Dermatitis : contact, atopic, occupational, drug最新文献

{"title":"Atopic Dermatitis and Emotional and Behavioral Outcomes in Urban U.S. Children: A Birth Cohort Study.","authors":"Moshe Schneiderman, Kristina M Derrick","doi":"10.1177/17103568251368268","DOIUrl":"https://doi.org/10.1177/17103568251368268","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Numerous studies suggest that childhood atopic dermatitis (AD) is associated with problems with internalizing behaviors. However, results for other behavioral domains, such as externalizing behaviors, attention problems, and social competence, have been mixed. <u><b><i>Objective:</i></b></u> To determine whether AD is associated with emotional/behavioral problems in a racially and ethnically diverse urban birth cohort of children of mostly unwed mothers. <u><b><i>Methods:</i></b></u> A total of 4898 mothers were recruited in maternity wards and followed longitudinally, completing questionnaires on AD and behavior at ages 5, 9, and 15. Logistic regression models compared the odds of emotional/behavioral problems in children with and without AD. <u><b><i>Results:</i></b></u> Adjusted analyses indicated children with AD were more likely to have internalizing (adjusted odds ratio [aOR] = 1.42; 95% confidence interval [CI]: 1.11-1.82) and externalizing (aOR = 1.48; 95% CI: 1.16-1.89) emotional/behavioral problems. <u><b><i>Conclusions:</i></b></u> Our findings underscore the importance of clinicians treating children with AD to specifically ask about emotional and behavioral problems, both at baseline and follow-up visits during AD treatment. This is crucial for early identification of behavioral problems and for monitoring responses to treatment. These assessments are also clinically significant in determining whether behavioral issues during AD treatment are preexisting or newly developed and avoiding AD treatments being incorrectly blamed for behavioral problems.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Extended Dosing Intervals of Dupilumab in Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.","authors":"Chi Peng Timothy Lai, Yew Yik Weng","doi":"10.1177/17103568251367706","DOIUrl":"https://doi.org/10.1177/17103568251367706","url":null,"abstract":"<p><p><u><b><i></i></b></u> Dupilumab is a biological agent used in atopic dermatitis (AD) with 2-weekly dosing. Extending dosing intervals in patients with a good response to dupilumab can lead to increased convenience, cost savings, and possibly fewer adverse events (AEs). There has been no systematic review or meta-analysis so far to assess the feasibility of extending dupilumab dosing intervals in well-controlled patients. This study aims to determine the efficacy and ocular AE occurrence in extended dosing intervals of dupilumab in comparison to the standard 2-weekly dosing regimen. We performed a systematic review and meta-analysis of articles using MEDLINE, EMBASE, Cochrane, and ClinicalTrials.gov which reported either efficacy (by measure of Eczema Area and Severity Index) or ocular AE occurrence in extended dosing interval regimens (3-weekly or 4-weekly dosing) in comparison to standard dosing regimens. Random effects analysis was used to obtain the pooled mean difference for efficacy and relative risk for ocular AEs. Thirteen reports from 11 studies were analysed. The pooled mean difference in the extended dosing interval regimen is 0.04 lower (95% confidence interval [CI]: -0.77 to 0.69) than the standard dosing regimen. The relative risk of ocular AEs in the extended dosing interval regimen in comparison to the standard dosing regimen is 0.58 (95% CI: 0.28-1.21). We conclude that extended dosing interval dupilumab regimens are at least as effective as standard dosing regimens in the treatment of AD in well-controlled patients. It cannot be concluded that ocular AEs are reduced with dose tapering. More work can be done to improve the current body of evidence for extended dosing intervals of dupilumab in AD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Changing Spectrum of Pediatric Allergic Contact Dermatitis: A Prospective Multicentric Study in Spain.","authors":"Nidia Planella-Fontanillas, David Pesqué, Leopoldo Borrego, Violeta Zaragoza Ninet, Javier Miquel Miquel, Tatiana Sanz-Sánchez, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera-Campos, Susana Córdoba Guijarro, Ricardo González Pérez, Esther Serra Baldrich, María Elena Gatica Ortega, Pedro Mercader-García, Inmaculada Ruiz Gonzales, Rubén Linares Navarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Mercedes Rodríguez Serna, María Antonia Pastor Nieto, Javier Sánchez Pérez, Araceli Sánchez Gilo, Gemma Melé-Ninot, Cristina Barrabés-Torrella, Enrique Gómez de la Fuente, Paloma Sánchez-Pedreño Guillén, Miguel Lova Navarro, Francisco Navarro Triviño, José Juan Pereyra Rodríguez, Ramon M Pujol, Miguel Ángel Descalzo, Ignacio García Doval, Ana M Giménez-Arnau","doi":"10.1177/17103568251368314","DOIUrl":"10.1177/17103568251368314","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Allergic contact dermatitis (ACD) is increasingly common in children, with age-related variations suggesting changing exposure patterns. <u><b><i>Objective:</i></b></u> Updating clinical and epidemiological characteristics, sensitization frequency, and relevance of positive patch tests in pediatric patients. <u><b><i>Methods:</i></b></u> This prospective multicenter study analyzed data from the Spanish Contact Dermatitis Research Group registry (REIDAC) for patients aged 0-16 years, stratified into 2 groups: 0-5 and 6-16 years. Participants were patch tested with the GEIDAC baseline and extended series from January 2019 to December 2023. <u><b><i>Results:</i></b></u> Patch tests were performed on 508 children, of whom 179 (35.2%) were sensitized. Among children aged 0-5 years (n = 41), 10 (24.4%) had positive patch tests, with lesions predominantly affecting the face (51.2%), hands (17.0%), and legs (4.9%). Atopic dermatitis (AD) was present in 36.6%, with linalool and limonene hydroperoxides as top sensitizers. In the 6-16 years group (n = 467), 169 patients (36.2%) were sensitized. AD was present in 45.0%, with lesions involving the face (24.0%), hands (23%), and legs (7.0%). Top allergens were linalool hydroperoxide and methylisothiazolinone. <u><b><i>Conclusions:</i></b></u> High sensitization proportions in both age groups highlight the importance of patch testing. Hydroperoxides of linalool and limonene are emerging as key sensitizers. Age-specific considerations may improve pediatric ACD management.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Biological Therapies for Prurigo Nodularis in Systemic Disease.","authors":"Elise Edwards, Kristiana Barbato, Peyton V Warp, Nicole Khalil, Andrea Maderal, Gil Yosipovitch","doi":"10.1177/17103568251367387","DOIUrl":"https://doi.org/10.1177/17103568251367387","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the Itch-Scratch Cycle: An Integrative Approach for Atopic Dermatitis.","authors":"Martin Steinhoff, Gil Yosipovitch, Ludivine Canchy, Bárbara Roque Ferreira, Claudia C Aguirre, Therdpong Tempark, Roberto Takaoka, Laurent Misery","doi":"10.1089/derm.2025.0021","DOIUrl":"https://doi.org/10.1089/derm.2025.0021","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease with a significant psychological impact. The cardinal symptom of all phenotypes and severities is chronic pruritus with repetitive itching and scratching due to a vicious itch-scratch cycle that can be worsened or triggered by stress. Neuroimaging of brain areas responsible for itch processing in healthy subjects versus patients with AD has provided insights into the brain circuits involved in itch central perception. In patients with AD, the dorsolateral prefrontal cortex appears to be overactive while regulating the itch-scratch circuit, and this persistent hyperactivation over time may disrupt this brain region. Common mechanisms between addiction and scratching could explain why some patients with AD continue to scratch despite showing clinical improvements from conventional treatments. In addition, molecular knowledge indicates bidirectional neuroimmune circuits between the peripheral nervous and immune system and dysregulated skin cells may aggravate and perpetuate AD severity. We provide an overview of the basic mechanisms that underlie the itch-scratch cycle in AD, especially neural sensitization of nonhistaminergic itch-specific pathways, and discuss how integrative therapies may interfere with central and peripheral mechanisms of chronic itch to reduce neuroinflammation and break the itch-scratch cycle. The connection between mind and body in the itch-scratch cycle, involving central mechanisms, suggests that integrative and multidisciplinary treatment approaches could be helpful as an adjunct to pharmacological treatment in the clinical management of AD. Integrative therapies may potentially help to reduce pruritus and scratching, psychological stress and sleep disturbances, and improve immune and skin barrier dysregulation, AD outcomes, and patient well-being.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"As Tears Go by: Blanched Streaks on the Cheeks From Tetrahydrozoline Eye Drops.","authors":"Shira Sandbank, Yoav Nahum, Daniel Mimouni, Yael A Leshem","doi":"10.1177/17103568251368277","DOIUrl":"https://doi.org/10.1177/17103568251368277","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shipboard Contact Dermatitis: An Understudied and Impactful Cause of Occupational Contact Dermatitis.","authors":"Kathleen E Kramer, Emily Beck, Vikas Shrivastava","doi":"10.1177/17103568251367701","DOIUrl":"https://doi.org/10.1177/17103568251367701","url":null,"abstract":"<p><p><u><b><i></i></b></u> Occupational contact dermatitis represents a significant concern within the United States Navy. Specifically, contact dermatitis that develops in a shipboard environment represents a unique concern, often leading to unplanned personnel losses. By identifying substances responsible for allergic and irritant contact dermatitis, dermatologists, through performing expanded patch testing and making recommendations to military commanders, play an important role in managing these patients, via ordering expanded patch testing panels and making recommendations to workplace commanders. This article aims to highlight gaps in knowledge of epidemiology and occupational hygiene, as well as make specific recommendations for patch testing in Navy personnel who serve aboard ships.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Testing for the Exploration of Immediate and Delayed Hypersensitivity to Fluoroquinolones: Insights From a Real-Life Cohort Study.","authors":"Julie Boo, Damien Lannoy, Johana Bene, Léa Dehame, Clémentine Dehouck, Delphine Staumont-Salle, Frédéric Dezoteux","doi":"10.1177/17103568251367789","DOIUrl":"https://doi.org/10.1177/17103568251367789","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Fluoroquinolones (FQ) are the second most frequent antibiotics responsible for hypersensitivity reaction (HSR). Data concerning the interest of allergological work-ups are scarce. <u><b><i>Objectives:</i></b></u> We reported a university center experience of the interest and safety of skin tests (ST) and drug provocation tests (DPT) for the exploration of immediate hypersensitivity reaction (IHR) and delayed HSR (DHR) to FQ. <u><b><i>Materials and Methods:</i></b></u> This retrospective study included patients tested for at least 1 FQ between 2008 and 2023. The primary outcome was the frequency of positive tests for FQ. Secondary outcomes aimed to characterize results, cross-reactivity, and tolerance of the tests. <u><b><i>Results:</i></b></u> Among the 113 patients included (32% in IHR, 68% in DHR), the overall test positivity rate was 27% (29% in DHR, 23% in IHR). Negative predictive value was 85% (80% in DHR, 95% in IHR). The most frequently positive ST was the intradermal test (7%). Allergy was more frequently confirmed for ofloxacin (OFX) (38%). Positive tests were more frequent for fixed drug eruption (67%). Cross-reactivity was detected in 15%, involving OFX and LFX or CPX and OFX. DPT was responsible for nonsevere recurrence of initial HSR for 13% of patients who had DPT and recurrence leading to a short hospitalization for 2% of them. 3% of contacted patients experienced a nonsevere recurrence of HSR in real life. <u><b><i>Conclusion:</i></b></u> This cohort demonstrates the benefit and safety of allergological exploration for FQ allowing subsequent use in 73% of cases.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Poor Responders to Lebrikizumab in Real-World Treatment for Atopic Dermatitis: Transition of Clinical and Laboratory Indexes.","authors":"Mizuki Shiba, Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1177/17103568251367796","DOIUrl":"https://doi.org/10.1177/17103568251367796","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Some patients with atopic dermatitis (AD) do not sufficiently respond to anti-interleukin-13 antibody lebrikizumab in real-world practice. Identifying predictive factors for poor responders to lebrikizumab is important to optimize treatment strategies for AD. <u><b><i>Objective:</i></b></u> To clarify predictive factors for poor responders to lebrikizumab, defined as patients with Investigator's Global Assessment >2 at week 12 or 24 of treatment in real-world practice. <u><b><i>Methods:</i></b></u> From May 2024 to April 2025, we conducted a prospective study in 124 Japanese AD patients treated with lebrikizumab. The transition of clinical and laboratory indexes was evaluated during 24-week lebrikizumab treatment, stratified by poor responders versus responders. We compared baseline characteristics between week 12 and 24 poor responders versus respective responders. <u><b><i>Results:</i></b></u> Both week 12 and 24 responders showed lower magnitudes of decreasing Eczema Area and Severity Index (EASI) throughout 24-week treatment compared with respective responders. Lactate dehydrogenase levels in both week 12 and 24 responders significantly decreased and plateaued at week 4, while there was no significant decrease in both week 12 and 24 poor responders. Total eosinophil count in both week 12 and 24 responders slightly increased at week 4 and 12, while there was no significant increase in both week 12 and 24 poor responders. Week 12 poor responders had higher baseline EASI compared with responders. Week 24 poor responders had higher body mass index (BMI) compared with responders. <u><b><i>Conclusions:</i></b></u> Higher baseline EASI may predict week 12 poor responders to lebrikizumab, while higher BMI may predict week 24 poor responders. These baseline characteristics could help optimize treatment for AD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Comparative Efficacy and Safety of Treatments for Periorificial Dermatitis: A Systematic Review.","authors":"Jia Qi Adam Bai, Ryan S Q Geng, Sana Gupta, Ary Kwun, Ilya Mukovozov","doi":"10.1177/17103568251368301","DOIUrl":"https://doi.org/10.1177/17103568251368301","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}